Rep. Gilbert Ray Cisneros, Jr. Sells Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BridgeBio Pharma stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $63.30 on Wednesday. The business’s 50-day simple moving average is $73.77 and its two-hundred day simple moving average is $73.44. The company has a market cap of $12.37 billion, a PE ratio of -17.73 and a beta of 0.97. BridgeBio Pharma, Inc. has a fifty-two week low of $52.75 and a fifty-two week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. During the same quarter in the previous year, the company earned ($0.95) earnings per share. The business’s revenue for the quarter was up 120.4% on a year-over-year basis. As a group, analysts predict that BridgeBio Pharma, Inc. will post -2.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Truist Financial raised their price target on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. HC Wainwright restated a “buy” rating on shares of BridgeBio Pharma in a research note on Tuesday, October 6th. Finally, Barclays dropped their price objective on shares of BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating on the stock in a report on Wednesday, October 7th. Twenty-one research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $105.42.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently modified their holdings of the stock. Silvant Capital Management LLC purchased a new stake in BridgeBio Pharma during the second quarter worth $28,000. Allworth Financial LP acquired a new stake in BridgeBio Pharma during the second quarter valued at $31,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BridgeBio Pharma during the second quarter valued at $44,000. Integrated Wealth Concepts LLC purchased a new position in BridgeBio Pharma in the second quarter valued at $52,000. Finally, Parallel Advisors LLC increased its holdings in BridgeBio Pharma by 552.6% in the first quarter. Parallel Advisors LLC now owns 894 shares of the company’s stock valued at $66,000 after buying an additional 757 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 34,980 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $82.53, for a total value of $2,886,899.40. Following the completion of the transaction, the chief executive officer owned 243,327 shares in the company, valued at approximately $20,081,777.31. This represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $80.06, for a total transaction of $160,120.00. Following the sale, the chief accounting officer directly owned 127,401 shares in the company, valued at approximately $10,199,724.06. The trade was a 1.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 56,980 shares of company stock valued at $4,578,119. Insiders own 14.23% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease.

BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions.